ARA: Could reach $4.50 if FDA Approvedhttps://www.scimitarequity.com/research/ARA_TO_Q1-2006.pdf
written here....
"We have not built the
SoftScan® regulatory approval into our FY06 price target.
FY06’s valuation could dramatically increase to our previous
guidance of $4.50 if SoftScan® is approved."